Yu Wu, Lei Zhao, Yufei Yang, Xinrong Xiang. "Venetoclax-based regimens are non-inferior to chemotherapy in core binding factor AML, including AML1-ETO." Blood, 2025. doi:10.1182/blood-2025-6965